GSK reports positive data from trial of cancer drug Dostarlimab
GSK said it would apply for marketing approval for Dostarlimab in endometrial cancer at the end of 2019.
New Delhi: GlaxoSmithKline said on Tuesday a study testing its experimental drug Dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.
Results from the GARNET study showed the drug elicited clinically meaningful and durable response rates when used to treat certain types of tumours, the company said.
Read Also: GSK Consumer profit rises 35 percent to Rs 221.06 crore in December quarter
GSK said it would apply for marketing approval for Dostarlimab in endometrial cancer at the end of 2019.
Dostarlimab was developed as part of a collaboration between Tesaro and AnaptysBio Inc.
GSK agreed to buy U.S. cancer specialist Tesaro for $5.1 billion in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.
Read Also: HUL expects to complete merger with GSK Consumer Healthcare in 2019
Anaptys Biocancercancer drugcancer in womencancer specialistCollaborationDostarlimabdrug dostarlimabendometrial cancerendometrial cancer drugGARNET studyGlaxoSmithKlineGSKGSK reportmedicinesovarian cancer Zejulapharma newsTesaroU SUnited StatesUS cancer specialist
Source : ReutersGarima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd